Market closed
KemPharm/$ZVRA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About KemPharm
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Ticker
$ZVRA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
67
Website
KemPharm Metrics
BasicAdvanced
$479M
Market cap
-
P/E ratio
-$2.11
EPS
1.93
Beta
-
Dividend rate
Price and volume
Market cap
$479M
Beta
1.93
52-week high
$8.76
52-week low
$4.20
Average daily volume
658K
Financial strength
Current ratio
2.884
Quick ratio
2.818
Long term debt to equity
85.118
Total debt to equity
85.892
Interest coverage (TTM)
-14.67%
Management effectiveness
Return on assets (TTM)
-32.80%
Return on equity (TTM)
-130.67%
Valuation
Price to revenue (TTM)
15.59
Price to book
6.84
Price to tangible book (TTM)
-86.2
Price to free cash flow (TTM)
-5.482
Growth
Revenue change (TTM)
47.85%
Earnings per share change (TTM)
200.87%
3-year revenue growth (CAGR)
-4.86%
3-year earnings per share growth (CAGR)
-10.61%
What the Analysts think about KemPharm
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for KemPharm stock.
KemPharm Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
KemPharm Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
KemPharm News
AllArticlesVideos
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
GlobeNewsWire·12 hours ago
Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 week ago
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for KemPharm stock?
KemPharm (ZVRA) has a market cap of $479M as of November 22, 2024.
What is the P/E ratio for KemPharm stock?
The price to earnings (P/E) ratio for KemPharm (ZVRA) stock is 0 as of November 22, 2024.
Does KemPharm stock pay dividends?
No, KemPharm (ZVRA) stock does not pay dividends to its shareholders as of November 22, 2024.
When is the next KemPharm dividend payment date?
KemPharm (ZVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for KemPharm?
KemPharm (ZVRA) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.